Literature DB >> 22843084

Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer.

David S Y Chan1, Christopher P Twine, Wyn G Lewis.   

Abstract

INTRODUCTION: The prognostic significance of human epidermal growth factor 2 (HER2) overexpression in patients diagnosed with oesophageal cancer is controversial. We performed a systematic review and meta-analysis to determine the influence of HER2 overexpression and amplification on outcomes in operable oesophageal cancer.
METHODS: MEDLINE and Embase (January 1990 to November 2011) was searched for translational studies that correlated HER2 expression with survival in operable oesophageal cancer.
RESULTS: Fourteen studies involving 1,464 patients who had undergone potentially curative oesophagectomy for oesophageal cancer [322 (22%) HER2-positive] were included. Five-year mortality was significantly higher in HER2-positive patients [odds ratio (OR) 1.43, 95% confidence interval (CI) 1.04 to 1.95, p = 0.03]. Analysis related to histological cell type demonstrated significantly higher 5-year mortality in HER2-positive squamous cell carcinoma [OR 2.88, 95% CI 1.34 to 6.17, p = 0.006] and adenocarcinoma [OR 1.91, 95% CI 1.15 to 3.17, p = 0.01] on sensitivity analysis of higher-quality studies.
CONCLUSION: HER2 overexpression and gene amplification in operable oesophageal cancer was an indicator of poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22843084     DOI: 10.1007/s11605-012-1979-2

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  27 in total

1.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

2.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

Review 3.  The ErbB receptors and their ligands in cancer: an overview.

Authors:  N Normanno; C Bianco; L Strizzi; M Mancino; M R Maiello; A De Luca; F Caponigro; D S Salomon
Journal:  Curr Drug Targets       Date:  2005-05       Impact factor: 3.465

4.  HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival.

Authors:  M Dreilich; A Wanders; D Brattström; S Bergström; P Hesselius; G Wagenius; M Bergqvist
Journal:  Dis Esophagus       Date:  2006       Impact factor: 3.429

5.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

6.  c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma.

Authors:  Masayuki Akamatsu; Toshiharu Matsumoto; Kuniyuki Oka; Shigetaka Yamasaki; Hiroshi Sonoue; Yoshiaki Kajiyama; Masahiko Tsurumaru; Keisuke Sasai
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-12-01       Impact factor: 7.038

7.  Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus.

Authors:  T Nakamura; H Nekarda; A H Hoelscher; E Bollschweiler; N Harbeck; K Becker; J R Siewert; N ] Harbec N [corrected to Harbeck
Journal:  Cancer       Date:  1994-04-01       Impact factor: 6.860

8.  Esophageal cancer chemotherapy: recent advances.

Authors:  David H Ilson
Journal:  Gastrointest Cancer Res       Date:  2008-03

9.  Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma.

Authors:  K Mimura; K Kono; M Hanawa; F Mitsui; H Sugai; N Miyagawa; A Ooi; H Fujii
Journal:  Br J Cancer       Date:  2005-04-11       Impact factor: 7.640

10.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  BMJ       Date:  2009-07-21
View more
  16 in total

1.  HER2 expression in gastric and oesophageal cancer: a meta-analytic review.

Authors:  Vinayak Nagaraja; Guy D Eslick
Journal:  J Gastrointest Oncol       Date:  2015-04

Review 2.  Biologic therapy in esophageal and gastric malignancies: current therapies and future directions.

Authors:  Pamela Samson; A Craig Lockhart
Journal:  J Gastrointest Oncol       Date:  2017-06

Review 3.  From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors.

Authors:  Federica Zoratto; L Rossi; E Giordani; M Strudel; A Papa; S Tomao
Journal:  Tumour Biol       Date:  2014-07-26

4.  Expression levels of HER2 and MRP1 are not prognostic factors of long-term survival in 829 patients with esophageal squamous cell carcinoma.

Authors:  Yong Chen; Shuang-Mei Zhu; Xiao-Ling Xu; A N Zhao; Jin-Lin Hu
Journal:  Oncol Lett       Date:  2015-11-25       Impact factor: 2.967

Review 5.  The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.

Authors:  Elisabeth J Diver; Rosemary Foster; Bo R Rueda; Whitfield B Growdon
Journal:  Oncologist       Date:  2015-06-22

6.  HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.

Authors:  Whitfield B Growdon; Jolijn Groeneweg; Virginia Byron; Celeste DiGloria; Darrell R Borger; Rosemary Tambouret; Rosemary Foster; Ahmed Chenna; Jeff Sperinde; John Winslow; Bo R Rueda
Journal:  Gynecol Oncol       Date:  2015-01-17       Impact factor: 5.482

7.  Forthcoming prognostic markers for esophageal cancer: a systematic review and meta-analysis.

Authors:  Vinayak Nagaraja; Guy D Eslick
Journal:  J Gastrointest Oncol       Date:  2014-02

8.  Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.

Authors:  Carrie L Robinson; Beth T Harrison; Azra H Ligon; Fei Dong; Valeria Maffeis; Ursula Matulonis; Marisa R Nucci; David L Kolin
Journal:  Mod Pathol       Date:  2020-10-19       Impact factor: 7.842

Review 9.  Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.

Authors:  L H McCormick Matthews; F Noble; J Tod; E Jaynes; S Harris; J N Primrose; C Ottensmeier; G J Thomas; T J Underwood
Journal:  Br J Cancer       Date:  2015-06-25       Impact factor: 7.640

10.  Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus.

Authors:  Julia Slotta-Huspenina; Karl-Friedrich Becker; Marcus Feith; Axel Walch; Rupert Langer
Journal:  Cancers (Basel)       Date:  2014-06-27       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.